Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dermapharm Holding SE (DMP)
Price€39.60Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €1.16B | €1.18B | €1.14B | €1.02B | €942.9M | €793.8M | €700.9M | €572.4M | €467.1M | €444.5M | €384.8M | €391.3M |
| Gross profit | €781.0M | €746.7M | €700.4M | €651.3M | €609.3M | €429.9M | €357.3M | €285.3M | €210.8M | €191.7M | €168.9M | €154.3M |
| Gross margin | 67.04% | 63.24% | 61.69% | 63.55% | 64.62% | 54.16% | 50.98% | 49.84% | 45.13% | 43.13% | 43.90% | 39.42% |
| Research & development | €11.2M | €11.5M | €10.6M | €13.2M | — | — | — | — | — | — | — | — |
| Operating expenses | €560.3M | €529.8M | €517.5M | €407.6M | €310.9M | €293.1M | €237.8M | €177.8M | €118.7M | €104.9M | €108.2M | €111.0M |
| Operating income | €220.7M | €216.9M | €182.9M | €243.7M | €298.5M | €136.8M | €119.5M | €107.5M | €92.1M | €86.8M | €60.8M | €43.3M |
| Operating margin | 18.94% | 18.37% | 16.11% | 23.78% | 31.65% | 17.24% | 17.05% | 18.78% | 19.72% | 19.53% | 15.79% | 11.05% |
| EBITDA | €324.7M | €307.4M | €287.5M | €344.9M | — | — | — | — | — | — | — | — |
| EBITDA margin | 27.88% | 26.04% | 25.32% | 33.65% | — | — | — | — | — | — | — | — |
| Net income | €131.3M | €111.7M | €60.5M | €132.6M | €208.9M | €85.9M | €77.8M | €75.2M | €77.7M | €77.0M | €52.4M | €33.2M |
| Net profit margin | 11.27% | 9.46% | 5.33% | 12.94% | 22.16% | 10.82% | 11.10% | 13.14% | 16.64% | 17.32% | 13.61% | 8.49% |
| Basic EPSper basic share | €2.46 | €2.11 | €1.16 | €2.49 | €3.89 | €1.60 | €1.45 | €1.40 | €0.41 | €0.32 | €0.29 | -€0.04 |
| Diluted EPSper diluted share | €2.46 | €2.11 | €1.16 | €2.49 | €3.88 | €1.60 | €1.45 | €1.40 | €0.41 | €0.32 | €0.29 | -€0.04 |